Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,876 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | terminated | Phase 3 | 218 | Polaris GroupINDUSTRY | 3 | Jun 25, 2026 | clinicaltrials |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | terminated | Phase 3 | 107 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00744185 | Propranolol in Capillary Hemangiomas(HEMANGIOMA) | terminated | Phase 2 / Phase 3 | 14 | University Hospital, BordeauxOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | terminated | Phase 3 | 175 | Rain Oncology IncINDUSTRY | 15 | Jan 14, 2025 | clinicaltrials |
| NCT04410042 | Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure | terminated | Phase 3 | 15 | St. Jude Children's Research HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | terminated | Phase 3 | 13 | University of California, IrvineOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients(METROPHOLYS) | terminated | Phase 3 | 79 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma(Tolerance) | terminated | Phase 3 | 14 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT03495921 | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide(VITA) | terminated | Phase 3 | 32 | Gradalis, Inc.INDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT00812240 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | terminated | Phase 3 | 335 | AB ScienceINDUSTRY | 3 | Feb 1, 2023 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT02739555 | Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma(BISPHOO) | terminated | Phase 3 | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | terminated | Phase 3 | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | terminated | Phase 3 | 2 | Instituto Valenciano de Infertilidad, IVI VALENCIAOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02929394 | Trabectedin Maintenance Post 1st-line in STS | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 2, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | terminated | Phase 3 | 1 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Apr 16, 2020 | clinicaltrials |
| NCT00870701 | Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma | terminated | Phase 3 | 77 | Institut Claudius RegaudOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03002454 | Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo | terminated | Phase 3 | 4 | University of ManitobaOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT00099177 | A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain | terminated | Phase 3 | 96 | Hoffmann-La RocheINDUSTRY | 16 | Aug 16, 2017 | clinicaltrials |
| NCT00099203 | A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease | terminated | Phase 3 | 163 | Hoffmann-La RocheINDUSTRY | 18 | Aug 16, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT02153593 | Postoperative Bleeding Prevention in Massive Bone Tumour Resection(TRANEXTUM) | terminated | Phase 3 | 56 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01743885 | Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma | terminated | Phase 3 | 55 | University Hospital, MontpellierOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00735553 | Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 77 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01189253 | Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma | terminated | Phase 2 / Phase 3 | 133 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 8, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT01031628 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | terminated | Phase 3 | 5 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | terminated | Phase 3 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00956072 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | terminated | Phase 3 | 12 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00427583 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | terminated | Phase 2 / Phase 3 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00372567 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | terminated | Phase 3 | 69 | PfizerINDUSTRY | 7 | Mar 17, 2011 | clinicaltrials |
| NCT00162695 | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood | terminated | Phase 3 | 400 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 13, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials